2. Academic Validation
  3. Recent advances of β-catenin small molecule inhibitors for cancer therapy: Current development and future perspectives

Recent advances of β-catenin small molecule inhibitors for cancer therapy: Current development and future perspectives

  • Eur J Med Chem. 2022 Dec 5:243:114789. doi: 10.1016/j.ejmech.2022.114789.
Panpan Yang 1,  Yumeng Zhu 1,  Qinwen Zheng 1,  Sha Meng 1,  Yongya Wu 1,  Wen Shuai 1,  Qiu Sun 2,  Guan Wang 3
Affiliations

Affiliations

  • 1 Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, 610041, China.
  • 2 Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, 610041, China. Electronic address: sunqiu@scu.edu.cn.
  • 3 Innovation Center of Nursing Research, Nursing Key Laboratory of Sichuan Province, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu, 610041, China. Electronic address: guan8079@163.com.
PMID: 36183504 DOI: 10.1016/j.ejmech.2022.114789
Abstract

The Wnt/β-catenin signaling pathway is involved in many cellular physiological processes, including embryonic development, cell proliferation and differentiation, tissue homeostasis and regeneration, etc. Aberrant activation of Wnt/β-catenin signaling is one of the most typical features in the development and progression of Cancer. Abnormal accumulation of β-catenin, a core component of the Wnt/β-catenin signaling pathway, is one of the main factors leading to abnormal activation of the Wnt/β-catenin signaling pathway. Therefore, β-catenin has become an important target for the development of Anticancer drugs. Some β-catenin small molecule inhibitors have been shown to have the potential to treat Cancer, such as the specific β-catenin/CBP antagonist PRI-724, which has entered phase I/II clinical trials. However, the development and application of β-catenin inhibitors are still challenging due to their selectivity, specificity and physicochemical properties, etc. This review introduces the Wnt/β-catenin signaling pathway, focuses on the research progress of β-catenin small molecule inhibitors, and prospects for the development of drug in the future.

Keywords

Cancer; Small molecule inhibitors; Wnt/β-catenin signaling pathway; β-catenin.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z